New hope for diabetics in treating blindness

June 03, 2002

Australian research has led to clinical trials of a drug that could provide a painless and non-destructive way to treat blindness in diabetics.

The University of Melbourne-led pre-clinical research prompted the world-wide, multi-centre clinical trial following the announcement of their results at an international conference last year. The drug blocks a crucial pathway whose end products cause blindness and eye damage in diabetics, the leading cause of new blindness in adults around the world. The trial will begin later this year.

The research team's success also caught the attention of funding agencies. The US-based Juvenile Diabetes Research Foundation (JDRF), the world's leading non-profit, non-governmental funder of diabetes research and the National Health and Medical Research Council (NHMRC) have granted the University of Melbourne team $4.7 million in funding over five years. The funds will help refine their understanding of the chemical pathways that lead to blindness (diabetic retinopathy) and kidney failure (diabetic nephropathy) in diabetics and to find new drugs to combat the disease.

"A vital clue to our breakthrough came unexpectedly when treating diabetics for high blood pressure, another consequence of the disease," says Dr Jennifer Wilkinsonson-Berka, Head of Diabetes and Vascular Biology Laboratory, University of Melbourne.

Wilkinson-Berka's team and other researchers working in this area found that common drugs used to treat high blood pressure also improved kidney problems. The chemical system in the body that caused high blood pressure in diabetics was found to be the same culprit behind kidney failure.

The system, called Renin-Angiotensin System (RAS) is triggered by high blood glucose levels and its end product is a protein call angiotensin that causes cells to grow.

Drugs used to treat high blood pressure block the chemical pathway in RAS that produces angiotensin.

"Diabetic patients now take these drugs to treat kidney damage, but nobody had thought to look if RAS also operated in the eye," says Wilkinson-Berka.

Using a diabetic rat model with an enhanced RAS that the team developed specifically for their diabetic research, they quickly discovered that RAS was present and active in the eye when blood glucose reached high levels.

"The diabetic rats also allowed us to test various drugs that attack the pathways affected by or involving glucose, including two angiotensin-blocking drugs similar to the new drug to be used in the clinical trial," says Wilkinson-Berka.

"We found that these drugs successfully prevented the growth of blood vessels in the eye and kidney. It was this success that led to the funding for, and approval of the clinical trial," she says.

Diabetic retinopathy occurs when the tiny blood vessels of the retina are damaged. The retina is a thin light-sensitive tissue at the back of the eye that transmits visual images to our brain.

The eye's vessels are extremely delicate. Angiotensin may cause the blood vessels to grow too fast and they fail to form properly. This causes the vessels to bleed and gradual detachment of the retina to occur. Similar damage occurs to the blood vessels in the kidney, eventually leading to kidney failure.

Current treatment for retinopathy is to burn hundreds of tiny holes into the retina with a laser to burn away damaged blood vessels. While effective, it is a damaging procedure causing loss of peripheral vision and it fails to prevent the problem re-occurring.

"We are aiming for a non-destructive, preventative treatment that doesn't involve destroying retina or requiring a kidney transplant," says Wilkinson-Berka.

More than 100,000 Australians have type 1 juvenile diabetes. It strikes suddenly and makes the recipient insulin dependent for life. With type 1 diabetes, the body's immune systems attacks and destroys the insulin-producing cells of the pancreas.

Insulin and a controlled diet do not cure diabetes, nor does it prevent the eventual and devastating effects such as kidney failure, nerve damage, amputations and blindness.

The JDRF and NHMRC grant will enable Dr Wilkinson-Berka's team to find other pathways and hormonal systems involved in nephropathy and retinopathy, and potential drugs to block these pathways.

"It is hoped that drugs such as the one being tested will retard or prevent visual impairment and blindness in diabetic patients. It will be a major advance in the treatment of a disease that affects a large proportion of the population including children and young adults," she says.
-end-
The research team includes Associate Professor Richard Gilbert and Dr Darren Kelly, Medicine, St Vincent's Hospital; Associate Professor Rik Thompon and Dr Mark Waltham, St Vincent's Institute; Professor George Werther and Dr Chris Wraight, Murdoch Children's Research Institute and Royal Children's Hospital; Professor Carol Pollock and Dr Philip Poronik, University of Sydney, Royal North Shore Hospital; Associate Professor Silviu Itescu, Columbia University, New York.

University of Melbourne

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.